Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8879774 | 0.80 | ALOX5 (0.52) | TDP1TP53LMNAMAPTCYP1A2 | |
| SCHEMBL2845356 | 0.79 | AMY1A (0.47) | AMY1ATDP1TP53LMNAMAPT | |
| SCHEMBL6546420 | 0.79 | AMY1A (0.47) | AMY1ATDP1TP53LMNAMAPT | |
| SCHEMBL11323718 | 0.79 | AMY1A (0.47) | AMY1ATDP1TP53LMNAMAPT | |
| SCHEMBL1610765 | 0.77 | AMY1A (0.46) | AMY1ATDP1TP53LMNAMAPT | |
| SCHEMBL8556572 | 0.76 | PTGS2 (0.41) | KDM4EBACE1 | |
| SCHEMBL8322153 | 0.76 | TRPA1 (0.52) | TDP1TP53LMNAMAPTALDH1A1 | |
| SCHEMBL9080019 | 0.76 | CYP3A4 (0.41) | TDP1MAPTCYP2A6ALDH1A1CYP3A4 | |
| SCHEMBL11243539 | 0.76 | ALOX15 (0.46) | LMNAMAPTALDH1A1CYP1A1CYP1B1 | |
| SCHEMBL3148637 | 0.76 | GABRA1 (0.50) | TDP1LMNAMAPTNQO2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2567964-B1 | Monomer compositions for the synthesis of RNA, methods of synthesis, and methods of deprotection | AGILENT TECHNOLOGIES INC (US) | 2015-02-11 | — | — | EP | claimed |
| EP-2567964-A2 | Monomer Compositions for the Synthesis of RNA, Methods of Synthesis, and Methods of Deprotection | Agilent Technologies, Inc. (US) | 2013-03-13 | — | — | EP | claimed |
| US-7759471-B2 | nucleotide monomer used to make protected RNA that has similar stability to the DNA molecule | AGILENT TECHNOLOGIES, INC. (US) | 2010-07-20 | — | — | US | claimed |
| US-20070100138-A1 | Monomer compositions for the synthesis of polynucleotides, methods of synthesis, and methods of deprotection | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2007-05-03 | — | — | US | claimed |
| US-20070100136-A1 | Monomer compositions for the synthesis of RNA, methods of synthesis, and methods of deprotection | AGILENT TECHNOLOGIES, INC. | 2007-05-03 | — | — | US | claimed |
| EP-3653613-B1 | 1,3-DI-SUBSTITUTED KETENE COMPOUND AND APPLICATION THEREOF | BEBETTER MED INC (CN) | 2022-11-16 | — | — | EP | disclosed |
| US-11306102-B2 | 1,3-di-substituted ketene compound and application thereof | BEBETTER MED INC. (CN) | 2022-04-19 | — | — | US | disclosed |
| US-20210122761-A1 | 1,3-DI-SUBSTITUTED KETENE COMPOUND AND APPLICATION THEREOF | BEBETTER MED INC. (CN) | 2021-04-29 | — | — | US | disclosed |
| EP-3653613-A1 | 1,3-DI-SUBSTITUTED KETENE COMPOUND AND APPLICATION THEREOF | Guangzhou Bebetter Medicine Technology Co., Ltd. (CN) | 2020-05-20 | — | — | EP | disclosed |
| EP-2567964-B1 | Monomer compositions for the synthesis of RNA, methods of synthesis, and methods of deprotection | AGILENT TECHNOLOGIES INC (US) | 2015-02-11 | — | — | EP | disclosed |
| US-8552174-B2 | Solutions, methods, and processes for deprotection of polynucleotides | AGILENT TECHNOLOGIES, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8420810-B2 | Bicyclic heterocyclic compound | Ono Pharmaceutical, Co., Ltd. (JP) | 2013-04-16 | — | — | US | disclosed |
| US-8202985-B2 | Monomer compositions for the synthesis of polynucleotides, methods of synthesis, and methods of deprotection | AGILENT TECHNOLOGIES, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-7759471-B2 | nucleotide monomer used to make protected RNA that has similar stability to the DNA molecule | AGILENT TECHNOLOGIES, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-20100137318-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-06-03 | — | — | US | disclosed |
| EP-2154139-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2010-02-17 | — | — | EP | disclosed |
| EP-1792909-A1 | Synthesis of polynucleotides | Agilent Technologies, Inc. (US) | 2007-06-06 | — | — | EP | disclosed |
| US-20070100138-A1 | Monomer compositions for the synthesis of polynucleotides, methods of synthesis, and methods of deprotection | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2007-05-03 | — | — | US | disclosed |
| US-20070100136-A1 | Monomer compositions for the synthesis of RNA, methods of synthesis, and methods of deprotection | AGILENT TECHNOLOGIES, INC. | 2007-05-03 | — | — | US | disclosed |
| US-20070100137-A1 | Solutions, methods, and processes for deprotection of polynucleotides | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070100136-A1 | Monomer compositions for the synthesis of RNA, methods of synthesis, and methods of deprotection | RNGTT, RNMT, NSUN2 | AMY1A 1922/4885TDP1 497/4885TP53 2653/4885 |
| US-20210122761-A1 | 1,3-DI-SUBSTITUTED KETENE COMPOUND AND APPLICATION THEREOF | PPARA, FABP1, PPARG | AMY1A 1393/4885TDP1 3265/4885TP53 2362/4885 |
| US-20070100138-A1 | Monomer compositions for the synthesis of polynucleotides, methods of synthesis, and methods of deprotection | POLN, NT5C3B, PCNA | AMY1A 2374/4885TDP1 192/4885TP53 2326/4885 |
| US-20070100137-A1 | Solutions, methods, and processes for deprotection of polynucleotides | POLN, POLRMT, POLM | AMY1A 1769/4885TDP1 81/4885TP53 984/4885 |
| US-11306102-B2 | 1,3-di-substituted ketene compound and application thereof | PPARA, FABP1, PPARG | AMY1A 1393/4885TDP1 3265/4885TP53 2362/4885 |
| US-20100137318-A1 | BICYCLIC HETEROCYCLIC COMPOUND | CRH, CRHR1, NR3C2 | AMY1A 931/4885TDP1 2485/4885TP53 3761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.